The Tool Desk
Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →Anti-obesity medications can help with weight management, but the strongest average weight-loss result is not automatically the best choice for an individual. In the United States, clinicians generally consider medication alongside nutrition, physical activity, and behavioral support for adults with a BMI of at least 30, or at least 27 with a weight-related health condition. Eligibility, benefits, and risks vary by medicine, age, medical history, and product label.
How do the main medication options compare?
The figures below are not a head-to-head ranking: semaglutide and tirzepatide were studied in separate placebo-controlled trials with different durations. Trial averages describe groups, not the weight change any one person should expect.
| # | Preview | Product | Price | |
|---|---|---|---|---|
| 1 |
|
Wegovy (Brand for Semaglutide, Auto-Injector) | Buy on Amazon |
As an Amazon Associate I earn from qualifying purchases.
| Option | Evidence or role | Route and practical points |
|---|---|---|
| Semaglutide 2.4 mg (Wegovy) | In STEP 1, investigators reported mean body-weight change of −14.9% at 68 weeks among adults without diabetes receiving semaglutide plus lifestyle intervention; the placebo group’s mean change was −2.4% (The New England Journal of Medicine, 2021). | Once-weekly injection in the trial. The FDA label includes specified weight-management uses and additional indications; see details below. |
| Tirzepatide (Zepbound) | In SURMOUNT-1, investigators reported mean weight change at 72 weeks of −15.0%, −19.5%, and −20.9% for the 5 mg, 10 mg, and 15 mg groups, respectively; placebo participants had a mean change of −3.1%. Participants did not have diabetes (The New England Journal of Medicine, 2022). | Once-weekly injection in the trial, with dose escalation. The FDA indication is for chronic weight management in specified adults. |
| Phentermine/topiramate ER (Qsymia) | FDA-labeled for chronic weight management with reduced-calorie eating and increased activity in adults and pediatric patients aged 12 or older with obesity, and adults with overweight plus a weight-related comorbidity. The sources cited here do not establish a comparable trial figure. | Oral medication. Pregnancy prevention and monitoring requirements are important; see the safety section. |
| Orlistat 60 mg (alli) | FDA-approved over-the-counter weight-loss aid for overweight adults aged 18 or older when used with a reduced-calorie, low-fat diet. It is not interchangeable with prescription-only options. | Oral OTC option. FDA updated its label in June 2026 to address rare acute kidney injury and kidney-stone concerns. |
Who may qualify, and what does eligibility mean?
U.S. professional guidance generally considers anti-obesity pharmacotherapy as an adjunct to diet, exercise, and behavioral modification for adults with BMI ≥30 kg/m², or BMI ≥27 kg/m² with an associated comorbidity. Those thresholds are not a guarantee that a person meets every product’s label, payer rules, or local eligibility requirements. Labels also differ by age and indication.
Quick wins for a faster PC:
Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Repair Windows errors before they cause bigger problemsFix Now →Scan for outdated or missing drivers - takes under a minuteDriver Scan →The American College of Physicians’ 2026 living guideline addresses nonpregnant adults in outpatient care and conditionally suggests semaglutide and tirzepatide among first-line options for specified groups. A 2025 Canadian guideline update addresses selecting, initiating, and using pharmacotherapy long term; country guidance and approvals differ. For a U.S. decision, the current FDA label and clinician assessment matter.
#1 Best Overall
What benefits do the best-known trial results show?
Semaglutide: STEP 1
STEP 1 was a double-blind trial of 1,961 adults without diabetes, with BMI ≥30 or BMI ≥27 plus at least one weight-related coexisting condition. Participants received once-weekly subcutaneous semaglutide 2.4 mg or placebo, alongside lifestyle intervention, for 68 weeks. The −14.9% mean body-weight change was the result for the semaglutide group reported by STEP 1 investigators; it is not an individual forecast.
Tirzepatide: SURMOUNT-1
SURMOUNT-1 was a phase 3, double-blind randomized trial of 2,539 adults without diabetes, with BMI ≥30 or BMI ≥27 plus at least one weight-related complication. Participants received weekly tirzepatide 5 mg, 10 mg, or 15 mg, or placebo, over 72 weeks including dose escalation. The reported group mean weight changes were −15.0%, −19.5%, and −20.9% at the respective tirzepatide doses, versus −3.1% with placebo.
The trials differed in duration and design and did not compare semaglutide directly with tirzepatide. Their averages therefore cannot show which medicine will work better for a particular person or guarantee a specific result.
Do these 3 things before closing this tab:
1Fix the driver behind crashes, sound loss and screen glitches2Clear out junk files and repair common Windows errors3Scan for outdated or missing drivers - takes under a minuteWhat risks and label issues deserve attention?
Semaglutide and tirzepatide
The 2026 FDA Wegovy label and FDA’s Zepbound approval information carry a boxed warning about thyroid C-cell tumors observed in rodents; whether this finding applies to humans is unknown. Wegovy is contraindicated for people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2 (MEN 2). The current label should be checked for complete contraindications and precautions.
Other label concerns differ by product. Wegovy’s label includes gastrointestinal effects and acute kidney injury related to volume depletion, among other precautions. FDA’s Zepbound announcement identifies warnings that include pancreatitis, gallbladder problems, hypoglycemia, and acute kidney injury. A clinician should review the full current prescribing information and a person’s medical history rather than relying on this abbreviated list.
Semaglutide’s FDA-labeled uses extend beyond weight management: they include cardiovascular risk reduction for adults with established cardiovascular disease and overweight or obesity, and an accelerated-approval MASH indication for a defined adult group. In FDA’s 2024 announcement on cardiovascular risk reduction, major adverse cardiovascular events occurred in 6.5% of participants receiving Wegovy versus 8% receiving placebo. The current label defines the precise indication; the FDA announcement is available at FDA’s Wegovy cardiovascular-risk approval announcement.
Qsymia
Qsymia is contraindicated during pregnancy. For patients who can become pregnant, the FDA label calls for a negative pregnancy test before treatment and monthly during treatment, along with specified laboratory monitoring. These requirements make pregnancy plans and reliable follow-up central to a prescriber’s risk assessment.
Orlistat (alli)
FDA’s June 10, 2026 communication describes rare acute kidney injury and updated label advice for people with kidney disease or a history of kidney stones, as well as symptoms to watch for. OTC availability does not remove the need to read the label or check whether a health condition or other medication changes the risk.
GLP-1 suicidal-thought warning status
Older articles may say that GLP-1 medicines carry a warning about suicidal thoughts or actions. On January 13, 2026, FDA said it found no increased risk with GLP-1 receptor agonists and requested removal of the corresponding warning from relevant labels. Check the current label for the particular product rather than relying on outdated summaries.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.How to choose an option to discuss with a clinician
There is no single best medication for everyone. The ACP’s 2026 living guideline says discussions about starting or switching should consider benefits, harms, costs, access and availability, comorbidities, weight-loss goals, life expectancy, values, preferences, contraindications, and warnings. A useful appointment can compare those factors explicitly.
- Health history: Bring up relevant diagnoses, prior medication reactions, pregnancy possibility or plans, and current medicines. Ask which label-specific contraindications or precautions apply.
- Goals: Clarify whether the priority is weight management, an additional labeled health benefit, or both, and what outcome would matter to you.
- How treatment fits: Compare oral versus injectable administration, dosing frequency, dose escalation, and the practical demands of continuing treatment. Confirm current instructions with the prescriber and product label.
- Access and affordability: Ask about coverage, out-of-pocket cost, and local availability before settling on a plan. Prices, coverage terms, and supply can vary; no cross-product price or availability comparison is established here.
- Follow-up: Agree how progress, side effects, and any needed monitoring will be reviewed, and what to do if treatment is not tolerated or does not meet agreed goals.
Is an over-the-counter or compounded GLP-1 product equivalent?
Among the medicines covered here, alli (orlistat 60 mg) is the FDA-approved OTC option described by FDA, for overweight adults aged 18 and older using the labeled reduced-calorie, low-fat diet. Do not assume that OTC status applies to prescription medicines.
FDA has also published concerns about unapproved GLP-1 products and advises vigilance about product and provider quality, dosing, and titration. For treatment decisions, use licensed clinical care and verify that a product is FDA-approved for its intended use; an unapproved product is not established as an equivalent substitute for an FDA-approved medicine.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
